CYP19A1 and breast cancer: A study by Yamashita et al. (2006) in 73 BC patients proved that p53 protein accumulation and high Ki67 expression are more resistant to aromatase inhibitors in metastatic disease patients (p-values of 0.0049 and 0.024, respectively) [24].